Advanced

Två genombrott i behandling av typ 2-diabetes. Både receptoragonist och enzymhämmare har nu nått kliniken.

Ahrén, Bo LU (2007) In Läkartidningen 104(49-50). p.3763-3764
Please use this url to cite or link to this publication:
@article{f1fc2c61-4ee5-4e15-a7a5-c8e5261f65fd,
  author       = {Ahrén, Bo},
  issn         = {0023-7205},
  keyword      = {Type 2: drug therapy,Enzyme Inhibitors: administration & dosage,Enzyme Inhibitors: therapeutic use,Glucagon-Like Peptide 1: metabolism,Hypoglycemic Agents: administration & dosage,Hypoglycemic Agents: therapeutic use,Nitriles: administration & dosage,Nitriles: therapeutic use,Peptides: administration & dosage,Peptides: therapeutic use,Pyrrolidines: administration & dosage,Pyrrolidines: therapeutic use,Receptors,Glucagon: drug effects,Venoms: therapeutic use,Venoms: administration & dosage,Diabetes Mellitus,CD26: antagonists & inhibitors,Antigens,Adamantane: therapeutic use,Adamantane: administration & dosage,Adamantane: analogs & derivatives},
  language     = {swe},
  number       = {49-50},
  pages        = {3763--3764},
  publisher    = {Sveriges Läkarförbund},
  series       = {Läkartidningen},
  title        = {Två genombrott i behandling av typ 2-diabetes. Både receptoragonist och enzymhämmare har nu nått kliniken.},
  volume       = {104},
  year         = {2007},
}